Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingolf Cascorbi

Showing results (51-60 of 192) with videos related to

Pageof 20
Sort By:
Pharmacogenetics and Genomics|April 19, 2014
Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379Anneke N Werk, Henrike Bruckmueller, Sierk Haenisch, et al.
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|July 8, 2026
Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementationCarina M Mathey, Martin Coenen, Ingolf Cascorbi, et al.
Frontiers in Pharmacology|October 2, 2025
The role of the lysine histone methylase KMT2D in chronic myeloid leukemiaLina Schlemminger, Inga Nagel, Inga Vater, et al.
Journal of Clinical Psychopharmacology|September 15, 2005
Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?Igor Mosyagin, Ingolf Cascorbi, Rainer Schaub, et al.
Frontiers in Pharmacology|August 6, 2024
Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasmsMeike Kaehler, Nikolas von Bubnoff, Ingolf Cascorbi, et al.
Oncology Letters|July 18, 2024
BTK acts as a modulator of the response to imatinib in chronic myeloid leukemiaLena Schmidlechner, Inga Nagel, Inga Vater, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2017
MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2Charles Awortwe, Meike Kaehler, Bernd Rosenkranz, et al.
Pharmacogenetics|October 3, 2002
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosusPetra Zschieschang, Falk Hiepe, Erika Gromnica-Ihle, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 27, 2013
Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3Necat Yilmaz A Sukru Aynacioglu Binnur Erbagci Ingolf Cascorbi Ivar Roots
Journal of Clinical Psychopharmacology|November 13, 2004
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosisIgor Mosyagin, Michael Dettling, Ivar Roots, et al.
Pageof 20

Showing results (51-60 of 192) with videos related to

Sort By:
Pageof 20
Pharmacogenetics and Genomics|April 19, 2014
Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379Anneke N Werk, Henrike Bruckmueller, Sierk Haenisch, et al.
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|July 8, 2026
Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementationCarina M Mathey, Martin Coenen, Ingolf Cascorbi, et al.
Frontiers in Pharmacology|October 2, 2025
The role of the lysine histone methylase KMT2D in chronic myeloid leukemiaLina Schlemminger, Inga Nagel, Inga Vater, et al.
Journal of Clinical Psychopharmacology|September 15, 2005
Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?Igor Mosyagin, Ingolf Cascorbi, Rainer Schaub, et al.
Frontiers in Pharmacology|August 6, 2024
Molecular biomarkers of leukemia: convergence-based drug resistance mechanisms in chronic myeloid leukemia and myeloproliferative neoplasmsMeike Kaehler, Nikolas von Bubnoff, Ingolf Cascorbi, et al.
Oncology Letters|July 18, 2024
BTK acts as a modulator of the response to imatinib in chronic myeloid leukemiaLena Schmidlechner, Inga Nagel, Inga Vater, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2017
MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2Charles Awortwe, Meike Kaehler, Bernd Rosenkranz, et al.
Pharmacogenetics|October 3, 2002
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosusPetra Zschieschang, Falk Hiepe, Erika Gromnica-Ihle, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|July 27, 2013
Implication of arylamine N-acetyltransferase (NAT2) polymorphism on levels of tumour markers CEA, AFP, CA 125, CA 19.9, and CA 15.3Necat Yilmaz A Sukru Aynacioglu Binnur Erbagci Ingolf Cascorbi Ivar Roots
Journal of Clinical Psychopharmacology|November 13, 2004
Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosisIgor Mosyagin, Michael Dettling, Ivar Roots, et al.
Pageof 20